	US 11,717,501 B2
	Magnesium threonate compositions and uses thereof
Guosong Liu, Oakland, CA (US); Fei Mao, Fremont, CA (US); and Jason Gregory Weinger, Concord, CA (US)
Assigned to Neurocentria, Inc., Walnut Creek, CA (US)
Filed by Neurocentria, Inc., Walnut Creek, CA (US)
Filed on Apr. 24, 2019, as Appl. No. 16/393,298.
Claims priority of provisional application 62/662,756, filed on Apr. 25, 2018.
Prior Publication US 2019/0328689 A1, Oct. 31, 2019
Int. Cl. A01N 43/40 (2006.01); A61K 31/44 (2006.01); C07D 413/04 (2006.01); C07D 413/14 (2006.01); A61K 31/191 (2006.01); A61K 9/00 (2006.01); A61P 25/28 (2006.01); A61K 31/20 (2006.01); A61K 33/06 (2006.01); A61K 47/44 (2017.01)

CPC A61K 31/191 (2013.01) [A61K 9/0053 (2013.01); A61K 31/20 (2013.01); A61K 33/06 (2013.01); A61K 47/44 (2013.01); A61P 25/28 (2018.01)]

19 Claims

1. A dosage form comprising magnesium threonate and a controlled release carrier, wherein:

at least a portion of magnesium (Mg) and threonate (T) of said magnesium threonate is present in a salt form of MgT₂;

said magnesium threonate is present in an amount between about 200 to 6000 mg; and

said controlled release carrier is present in the dosage form in an amount sufficient to provide an in vivo plasma profile that exhibits a fluctuation index that is less than about 170%.